151 related articles for article (PubMed ID: 36049103)
1. Pancreatic Adenocarcinoma Associated to Intraductal Papillary Mucinous Neoplasia: Histopathological Particularities and Clinical Implications.
Schlanger D; Popa C; Rusu I; Hajjar NA
Chirurgia (Bucur); 2022 Jun; 117(4):454-462. PubMed ID: 36049103
[No Abstract] [Full Text] [Related]
2. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma.
Fogliati A; Zironda A; Fiorentini G; Adjei S; Amro A; Starlinger PP; Grotz TE; Warner SG; Smoot RL; Thiels CA; Kendrick ML; Cleary SP; Truty MJ
Ann Surg Oncol; 2024 Apr; 31(4):2632-2639. PubMed ID: 38319513
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in the Remnant Pancreas.
Matsuda R; Miyasaka Y; Ohishi Y; Yamamoto T; Saeki K; Mochidome N; Abe A; Ozono K; Shindo K; Ohtsuka T; Kikutake C; Nakamura M; Oda Y
Ann Surg; 2020 May; 271(5):941-948. PubMed ID: 30308608
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
[TBL] [Abstract][Full Text] [Related]
7. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma.
Holmberg M; Ghorbani P; Gilg S; Del Chiaro M; Arnelo U; Löhr JM; Sparrelid E
Pancreatology; 2021 Oct; 21(7):1371-1377. PubMed ID: 34426077
[TBL] [Abstract][Full Text] [Related]
8. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
[TBL] [Abstract][Full Text] [Related]
9. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma.
Capretti G; Nebbia M; Gavazzi F; Nappo G; Ridolfi C; Sollai M; Spaggiari P; Bozzarelli S; Carrara S; Luberto A; Zerbi A
Pancreatology; 2022 Sep; 22(6):782-788. PubMed ID: 35701318
[TBL] [Abstract][Full Text] [Related]
10. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.
Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2022 Jun; 22(5):598-607. PubMed ID: 35501218
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma.
Koh YX; Chok AY; Zheng HL; Tan CS; Goh BK
Ann Surg Oncol; 2014 Aug; 21(8):2782-800. PubMed ID: 24687151
[TBL] [Abstract][Full Text] [Related]
12. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
[TBL] [Abstract][Full Text] [Related]
13. Risk of Recurrence After Surgical Resection for Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasia (IPMN) With Patterns of Distribution and Treatment: An International, Multicenter, Observational Study (ADENO-IPMN Study).
Lucocq J; Hawkyard J; Robertson FP; Haugk B; Lye J; Parkinson D; White S; Mownah O; Zen Y; Menon K; Furukawa T; Inoue Y; Hirose Y; Sasahira N; Feretis M; Balakrishnan A; Zelga P; Ceresa C; Davidson B; Pande R; Dasari B; Tanno L; Karavias D; Helliwell J; Young A; Nunes Q; Urbonas T; Silva M; Gordon-Weeks A; Barrie J; Gomez D; van Laarhoven S; Doyle J; Bhogal R; Harrison E; Roalso M; Ciprani D; Aroori S; Ratnayake B; Koea J; Capurso G; Bellotti R; Stättner S; Alsaoudi T; Bhardwaj N; Jeffery F; Connor S; Cameron A; Jamieson N; Sheen A; Mittal A; Samra J; Gill A; Roberts K; Soreide K; Pandanaboyana S
Ann Surg; 2024 Jul; 280(1):126-135. PubMed ID: 37873663
[TBL] [Abstract][Full Text] [Related]
14. Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis.
Reid MD; Stallworth CR; Lewis MM; Akkas G; Memis B; Basturk O; Adsay V
Cancer Cytopathol; 2016 Feb; 124(2):122-34. PubMed ID: 26415076
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm.
Tanaka T; Kuroki T; Adachi T; Ono S; Hirabaru M; Soyama A; Kitasato A; Takatsuki M; Hayashi T; Eguchi S
Pancreas; 2013 Apr; 42(3):488-93. PubMed ID: 23146920
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience.
Marsoner K; Haybaeck J; Csengeri D; Waha JE; Schagerl J; Langeder R; Mischinger HJ; Kornprat P
BMC Cancer; 2016 Nov; 16(1):844. PubMed ID: 27809876
[TBL] [Abstract][Full Text] [Related]
18. Synchronous Pancreatic Tumours: Intraductal Papillary Mucinous Neoplasm with Pancreatic Ductal Adenocarcinoma and Neuroendocrine Tumour: A Case Presentation and Review of Literature.
Schlanger D; Popa C; Rusu I; Seicean A; Hajjar NA
Chirurgia (Bucur); 2021 Aug; 116(eCollection):1-9. PubMed ID: 34463245
[TBL] [Abstract][Full Text] [Related]
19. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm".
Matsuda R; Miyasaka Y; Yamada Y; Kawata J; Sakihama K; Yamamoto T; Saeki K; Yamamoto H; Ohishi Y; Koga Y; Nakamura M; Oda Y
Virchows Arch; 2020 Dec; 477(6):799-806. PubMed ID: 32468246
[TBL] [Abstract][Full Text] [Related]
20. Metachronous occurrence of main-duct intraductal papillary mucinous neoplasm (IPMN) and adenocarcinoma in a chronic pancreatitis patient: A case report.
Jee KN
Medicine (Baltimore); 2022 Feb; 101(6):e28770. PubMed ID: 35147102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]